GxP validation for AI works only when it is risk-based, lifecycle-managed, and audit-ready from day one. The reference points that matter right now are the ISPE GAMP Guide on Artificial Intelligence, the FDA's January 2025 draft AI guidance, and the EU's draft GMP Annex 22. Teams that need help translating that into an operating model, rather than another binder, sometimes bring in a partner like Haiphai to run the lifecycle alongside them.
TL;DR:
- Validation efforts must be risk-based and follow a lifecycle approach, including stages from intended use through monitoring and eventual retirement.
- Clear and detailed intended-use statements with defined scope, inputs, outputs, user actions, and limitations are essential before starting validation.
- Test data must be independent, well-documented, and representative, with control over rare high-risk cases to ensure accurate performance measurement.
- Validation requires comprehensive documentation, including traceability matrices, data inventories, and sign-offs from subject-matter experts and QA before testing begins.
- Continuous monitoring and revalidation are critical post-deployment to detect drift, verify performance, and prevent model degradation, especially for high-risk applications.
Table of Contents
- What Is a Practical Lifecycle Framework for GxP AI Validation?
- How Do You Define Intended Use and Set Acceptance Criteria?
- How Do You Build an Audit-Ready Test Data Plan?
- What Should Go Into a GxP AI Test Plan?
- When Do You Need Explainability and Confidence Thresholds?
- How Do You Monitor and Revalidate an AI Model in Production?
- What Documentation Do Auditors Expect for GxP AI Systems?
- A Copyable Checklist for Getting Started
- Notes From Practice: What Haiphai Sees on the Ground
- What the Industry Gets Wrong About AI Validation
- Haiphai as an Operational Partner for GxP AI Validation
- Sources
- FAQ
What Is a Practical Lifecycle Framework for GxP AI Validation?
Most AI validation failures in GxP settings trace back to one mistake: treating validation as a single event at go-live instead of a lifecycle that runs from concept to retirement. The Integrated Validation, Ethics, and Lifecycle model, known as IVEL, sequences regulatory, technical, and ethical activities into stages a quality team can actually execute against, rather than a set of principles to interpret from scratch.
The stages look like this in practice:
- Intended use. Define what the model does, who uses it, and what decision it informs, before any code gets written.
- Design. Select an architecture and data strategy proportional to risk. A simple logistic model for batch record anomaly flags does not need the same scrutiny as a generative tool drafting regulatory submissions.
- Development. Build with reproducible pipelines, version-controlled training data, and documented hyperparameters.
- Testing. Execute a pre-approved test plan against independent data, with acceptance criteria set before results come in.
- Deployment. Move into production only after QA sign-off, with rollback plans documented.
- Monitoring. Track live performance, input drift, and audit logs continuously, not just at scheduled reviews.
- Change control and retirement. Decide, using pre-set rules, when a model update or performance drop triggers revalidation or decommissioning.
Each stage maps to a GxP control and a deliverable an inspector can request by name. Intended use produces a signed use statement. Design produces a risk assessment. Testing produces a traceability matrix linking requirements to test cases to results. Monitoring produces drift logs and periodic review records.
Risk-based scoping decides how deep each stage goes. A model that scores marketing email subject lines carries different stakes than one flagging deviations in a batch record or drafting language for a regulatory submission. The ISPE GAMP guide recommends tailoring validation effort to the organization's own experience with a given AI approach and to how directly the system's output touches product quality, patient safety, or data integrity. A model with a human reviewing every output before it acts on a batch record needs less validation depth than one operating with full autonomy on the same decision.
The FDA's January 2025 draft AI guidance pushes in a similar direction: match rigor to risk rather than applying one fixed validation template across every AI use case. The EU's approach, expressed through Annex 22, tends to be more prescriptive about specific controls, including test-data independence and explainability documentation. Practitioners running programs across both jurisdictions need to design for the stricter standard and treat the lighter one as a floor, not a ceiling.
How Do You Define Intended Use and Set Acceptance Criteria?
An intended-use statement is the single document that determines everything downstream, and most teams write it too vaguely to be testable. "Assists with deviation triage" tells an auditor nothing. "Classifies incoming deviation reports into one of five severity categories to prioritize QA review queue order, with a human QA reviewer making the final categorization decision" gives you something you can actually validate against.
A workable intended-use statement needs four elements:
- Scope. What process or decision the AI touches, and what it explicitly does not touch.
- Inputs and outputs. The exact data going in and the exact format coming out, including confidence scores if applicable.
- User actions. What a human does with the output. Accept, review, override, or escalate.
- Limitations. Known failure modes, excluded populations or product types, and conditions under which the system should not be used.
Acceptance criteria translate that statement into numbers you can defend before you see a single result. For a classification model flagging potential deviations, a criterion might read: sensitivity of 95% or higher on the validation set, specificity of 90% or higher, and a critical error rate (missed high-severity events) below 1%. For a document-drafting tool assisting regulatory submissions, criteria might focus on factual consistency against source documents and a defined rate of hallucinated citations, checked manually against a sample.
F1 score works well when you need a single number balancing precision and recall, but it can mask a dangerous asymmetry. A model with strong overall F1 can still miss the rare, high-severity cases that matter most in a GxP context, so pair F1 with a critical error rate specific to the highest-risk category.
Pro Tip: Write your acceptance criteria and get subject-matter expert and QA sign-off before you run a single test. Criteria set after seeing results are not acceptance criteria. They are rationalizations.
Sign-off needs two signatures at minimum: a subject matter expert confirming the criteria reflect real-world risk, and QA confirming the criteria are measurable and traceable. Skipping either signature is the fastest way to get a validation package rejected on inspection.
How Do You Build an Audit-Ready Test Data Plan?
Test-data independence is the single most contested item in AI validation audits, and Annex 22 is direct about it: staff involved in testing should not participate in model training, and organizations must record which data was used for testing and how many times. That second point catches teams off guard. Reusing a validation set to "just check" a model during development quietly contaminates it, and if you cannot prove otherwise, an auditor has to assume it happened.
Independence needs both technical and procedural controls. Technical controls include separate data repositories for training versus test sets, access controls that log who touched which dataset and when, and version tags that tie a specific test dataset to a specific test run. Procedural controls include distinct teams for model development and test execution, plus a documented four-eyes check when full team separation is not realistic in a smaller organization.
Sample size and composition matter as much as independence. A test set of 200 records might look sufficient until you realize the rare, high-severity cases you actually care about only appear five times in that set. Stratified sampling forces representation across subgroups, whether that means product types, patient populations, deviation severities, or document categories, so the model gets tested against the cases where failure carries the highest consequence, not just the cases that are easy to find.
Rare-case inclusion deserves a deliberate strategy rather than hoping enough show up naturally. If a severe adverse event pattern occurs in 0.3% of real-world data, a randomly sampled test set of a few hundred records may contain zero examples. Oversample rare, high-risk cases intentionally, then document that you did so and why, so the reported performance numbers are not misread as reflecting real-world prevalence.
A few concrete controls to build into every test data plan:
- Maintain an immutable inventory logging every dataset used, its source, its labeling method, and every occasion it was accessed for testing.
- Verify labels through a second independent reviewer for any subset used in acceptance testing, not just spot checks.
- Pre-specify every preprocessing step (normalization, encoding, missing-value handling) in the test plan before running the model, and embed that preprocessing directly into the saved model pipeline. The TensorFlow guidance on loading and preprocessing data is a useful reference for keeping preprocessing reproducible between training and production, so a mismatch between environments does not silently invalidate your test results.
- Segregate staff roles so the people who curate or label training data are not the same people who sign off on test results.
Annex 22's independence rule exists because auditors have seen the alternative: a model that looks excellent on paper because it was quietly tuned against the same data used to prove it works. Documented separation, an immutable data inventory, and pre-specified preprocessing are what turn a plausible validation story into one that survives an inspection.
What Should Go Into a GxP AI Test Plan?
A test plan for an AI system needs six sections at minimum, and skipping any one of them is the most common reason validation packages bounce back from QA review: scope, datasets used, test scripts or procedures, metrics with thresholds, acceptance criteria, and a traceability matrix connecting each requirement to its corresponding test case and result.
Metric selection depends heavily on what the model actually does:
- Classification models (deviation triage, defect detection): sensitivity, specificity, positive predictive value, and a critical error rate specific to the highest-severity category.
- Regression models (shelf-life prediction, yield forecasting): mean absolute error and root mean square error, benchmarked against a clinically or operationally meaningful tolerance, not just a statistical baseline.
- Retrieval models (finding relevant SOPs or prior deviations): precision at the top results returned and recall across the known relevant set.
- Generative models (drafting regulatory text, summarizing study reports): factual consistency against source documents, hallucination rate on a sampled review, and stylistic or format compliance where regulatory submissions have fixed structural requirements.
Subgroup cutoffs matter more than the headline number. A model reporting 96% overall accuracy that drops to 78% for one product line or one patient subgroup has a real problem the aggregate number is hiding. Set subgroup-specific acceptance thresholds wherever a subgroup carries distinct risk, not just an overall pass/fail line.
Some organizations now automate parts of test execution by using AI to generate large volumes of test inputs and a separate model to score outputs, scaling coverage well beyond what manual test-case writing can achieve. The tradeoff is that regulators will expect proof the evaluation tool is independent from the model under test, with subject-matter experts still reviewing the highest-risk cases by hand rather than trusting automated scoring end to end.
Deviations during testing need the same rigor as manufacturing deviations: root cause, impact assessment, and a documented decision on whether the deviation blocks release or gets accepted with justification. A model that fails its critical error rate threshold on one subgroup is not a footnote. It is a deviation that needs its own investigation record.
When Do You Need Explainability and Confidence Thresholds?
Explainability techniques earn their place when a human downstream needs to understand why the model produced a given output, not as a default add-on for every model regardless of use case. Feature-attribution methods like SHAP or LIME make sense for a model flagging which batch parameters drove an anomaly score, because a QA reviewer needs that reasoning to act on the flag correctly. They add less value for a well-understood, low-risk classification task where the output itself is the entire decision.
Whatever explainability method you choose, record three things as evidence: the method used, the specific outputs it was applied to, and how a reviewer used that explanation to reach a decision. An unused explainability report sitting in a folder does not satisfy an auditor asking how a human oversight step actually worked.
Confidence thresholds are where a lot of AI validation programs quietly fail. A model that always returns an answer, even when it should not be confident enough to do so, pushes risk downstream onto a human who may not realize the output deserves extra scrutiny. Build an explicit "undecided" or "needs review" flag for any output below a defined confidence threshold, and route that flag to a human reviewer automatically rather than letting a low-confidence output blend in with a high-confidence one.
Pro Tip: Set your confidence threshold using the cases you most fear missing, not the cases you most often see. A threshold tuned only against common cases will let the rare, dangerous ones slip through with false confidence.
Generative AI needs its own tier of controls. Annex 22 explicitly excludes generative AI from critical GMP applications given the difficulty of proving deterministic, testable behavior for a system that can produce novel outputs each time. That does not rule out generative tools for lower-risk supporting tasks, like drafting a first pass of a regulatory document a human then reviews line by line, but it does mean:
- Generative outputs used in any GxP-critical decision need mandatory human review before action, with no exceptions.
- Hallucination and factual-consistency checks need to run on every batch, not a periodic sample.
- Version and prompt changes to a generative model count as a change requiring the same scrutiny as any other model update.
How Do You Monitor and Revalidate an AI Model in Production?
Validation does not end at deployment. Production monitoring needs to track four categories of signal continuously: model performance against ground truth where available, input data distributions compared to training data, data quality issues feeding the model, and audit logs of every decision the model influenced.
Drift shows up in two forms that require different responses. Data drift means the inputs the model sees in production look statistically different from its training data. A new supplier's raw material specs, a new instrument's output format, or a seasonal shift in patient demographics can all produce this. Concept drift means the underlying relationship the model learned has itself changed. A deviation-triage model trained before a process change may keep scoring confidently while actually being wrong about what matters now.
Automated drift detection tools compare live input distributions against a stored training-data baseline and flag statistically significant divergence. Set an escalation path before you need it: a defined drift threshold routes to a data science review, a defined performance drop routes to QA, and either one crossing a hard limit freezes the model from further autonomous use until reviewed.
Practical monitoring priorities:
- Track performance metrics on any cases where ground truth eventually becomes available (confirmed deviations, corrected classifications).
- Compare input feature distributions against the training baseline on a fixed schedule, not only when something looks wrong.
- Log every model decision with enough detail to reconstruct it during an audit, including confidence scores and any human override.
- Set a revalidation cadence tied to risk tier: high-risk models reviewed quarterly at minimum, lower-risk models on an annual cycle, with any detected drift or model update triggering an off-cycle review regardless of the calendar.
Change control decides what triggers revalidation versus what gets logged as a minor update. A model retrained on new data, a change to the training pipeline, or a shift in the underlying software platform all warrant a documented impact assessment before release. A cosmetic dashboard change to how results are displayed generally does not, but the decision rule itself needs to be written down in advance, not improvised case by case.
What Documentation Do Auditors Expect for GxP AI Systems?
Auditors reviewing an AI validation package look for a specific set of documents, and missing any one of them is a near-automatic finding. At minimum, keep a requirements-to-test traceability matrix, a full test-plan archive with executed results, a dataset inventory logging every dataset's provenance and use, and a change-control log capturing every model update with its impact assessment.
Vendor-supplied AI tools add a layer most teams underestimate; confirming adherence to GMP manufacturing requirements is critical before qualifying a vendor's model. Before qualifying a vendor's model, confirm you have contractual access rights to review the model's validation evidence, clarity on intellectual property and data ownership, audit rights that let your QA team inspect the vendor's own controls, and documented evidence of the training data's provenance. A vendor unwilling to provide any of these is a vendor you cannot validate against, no matter how good the demo looks. A structured vendor qualification workflow gives QA teams a repeatable way to check these boxes instead of relying on ad hoc contract review each time.
Pro Tip: Ask a vendor for their model card or equivalent documentation before the contract is signed, not after. If they cannot produce one, budget extra validation time to fill the gaps yourself.
Staff training and segregation controls close the loop. Define roles explicitly: who develops the model, who curates training data, who executes tests, who approves acceptance criteria, and who monitors production. The same person should not hold conflicting roles across that list, and training records proving each person understood their specific responsibilities belong in the same package as the technical evidence. The ISPE GAMP guide's emphasis on stakeholder collaboration and continuous monitoring exists precisely because AI validation, unlike a one-time software qualification, needs ongoing coordination between roles that traditional CSV never demanded.
A Copyable Checklist for Getting Started
Start with scoping, not tooling. Before selecting a model or vendor, work through this sequence:
- Draft the intended-use statement and get SME and QA sign-off.
- Assign a risk tier based on impact to product quality, patient safety, or data integrity.
- Set acceptance criteria and metric thresholds before any testing begins.
- Assemble an independent, stratified test dataset with documented provenance.
- Execute the test plan and log every deviation with root cause and disposition.
- Define confidence thresholds and human-review triggers before go-live.
- Establish production monitoring and a revalidation cadence tied to risk tier.
A short intended-use template you can adapt directly: "This system [action] for [user role] to support [decision], using [input types] to produce [output type], with [human role] making the final determination. It is not intended for [excluded use case]."
An example acceptance-criteria line for a classification use case: "Sensitivity ≥95%, specificity ≥90%, critical error rate <1% on the stratified validation set, reviewed and approved by QA and the process SME prior to test execution."
A minimal test-plan header should capture: system name and version, intended-use reference, risk tier, dataset identifiers, metrics and thresholds, and approver signatures with dates.
For prioritizing where to spend limited validation resources, weigh two factors against each other:
- High risk, high complexity (generative drafting tools touching regulatory submissions): full lifecycle rigor, quarterly revalidation, mandatory human review of every output.
- Low risk, low complexity (an internal scheduling assistant): lighter documentation, annual review, spot-check monitoring.
Most real programs sit somewhere between those two poles, and the ISPE GAMP guide's risk-based philosophy exists specifically to keep you from over-validating the low-risk cases and under-validating the ones that actually matter.
Notes From Practice: What Haiphai Sees on the Ground
Author's note: this section reflects Haiphai's operational work with biotech regulatory and clinical operations teams; a fuller author bio and detailed case studies are forthcoming.
Teams rarely fail AI validation because they lack technical talent. They fail because the intended-use statement was vague, the test data was not documented as independent, or nobody set a revalidation trigger before the model drifted quietly for months. Haiphai's engagements with biotech clients consistently point to the same pattern: operational bottlenecks around regulatory drafting and clinical site activation get worse, not better, when AI is bolted onto an existing process without a lifecycle plan behind it.
A few signals worth tracking if you want a sense of what a well-run program looks like in practice:
- Clients report reclaiming significant operational timeline when AI adoption is paired with a structured, risk-based rollout rather than an unmanaged pilot.
- An operational-partnership model, where the same team maps bottlenecks and builds the AI workflow, tends to close gaps faster than handing a validation checklist to an internal team already stretched thin.
For teams building out their own internal capability, the guide to AI in regulatory document drafting and the overview of AI integration in life sciences go deeper into specific workflow examples.
What the Industry Gets Wrong About AI Validation
Most guidance on this topic treats validation as a compliance tax, something you pay once to get past an inspection and then forget about. That framing produces exactly the failures Annex 22's independence rules and the FDA's risk-based language are trying to prevent: models that looked fine at go-live and quietly degraded because nobody built monitoring into the plan from the start.
The bigger blind spot is documentation discipline around test data. Teams will spend weeks tuning a model's architecture and five minutes documenting where the test set came from. Auditors increasingly focus there first, because a model's accuracy number means nothing if you cannot prove the data behind it was genuinely independent.
If you take one thing from this framework, prioritize the intended-use statement over the model itself. A vague intended-use statement makes every downstream step, acceptance criteria, test design, monitoring thresholds, weaker by inheritance. Get that document right, with real SME and QA sign-off, before you touch a single line of validation code.
— John
Haiphai as an Operational Partner for GxP AI Validation
Building a compliant AI lifecycle from scratch, while also running your actual regulatory and clinical timelines, is where most internal teams get stretched thin. Haiphai works as an embedded operational partner rather than a software vendor, mapping your specific bottlenecks in regulatory drafting or clinical site activation and then building the validated AI workflow around that diagnosis instead of offering a one-size-fits-all platform.
Engagements typically start with a diagnostic phase to identify where AI can realistically compress timelines, followed by an arrangement to design, validate, and govern the workflow alongside your existing quality system. Clients preparing for an initial engagement should have a rough map of their current bottlenecks and a point of contact from QA who can participate in acceptance-criteria sign-off early. The goal on every engagement is regulatory readiness paired with a shorter path to approval, with clients reporting significant time reclaimed on that path. If your team is weighing how to structure a GxP-compliant AI rollout, Haiphai to talk through where your specific timeline is losing the most time.
Sources
- ISPE GAMP® Guide: Artificial Intelligence
- EU GMP Annex 22 consultation document (Annex 22)
- Validation, ethics, and lifecycle governance of AI and machine learning in GxP applications: a comparative regulatory analysis and integrated framework | Springer
- TensorFlow tutorial: Load CSV data
This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.
FAQ
Does a GxP system need to be validated?
Yes. Any computerized system, including AI models, used in a GxP process must be validated to demonstrate it is fit for its intended use, with documented evidence covering design, testing, and ongoing performance.
What is the 30% rule in AI?
There is no established "30% rule" in GxP AI validation guidance from ISPE, the FDA, or Annex 22; if you have seen this term elsewhere, treat it as informal shorthand rather than a recognized regulatory standard.
How do you validate an AI system in a GxP environment?
Define an intended-use statement, set measurable acceptance criteria before testing, run the test plan against independent and representative data, and follow deployment with continuous monitoring and a defined revalidation trigger, following the risk-based approach described in the ISPE GAMP guide and Annex 22.
What does GxP validation mean for an AI model specifically?
It means proving, with documented and traceable evidence, that the AI model consistently performs its intended function within defined acceptance criteria, using independent test data and ongoing monitoring rather than a one-time check at launch.
Can a company get help implementing GxP AI validation instead of building it internally?
Yes. Some biotech teams bring in an operational partner like Haiphai to design and run the validation lifecycle alongside existing regulatory and clinical operations, rather than building the capability entirely in-house.